Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD
06. Oktober 2020 07:48 ET
|
Oxford BioMedica plc
Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase 2 trial of AXO-Lenti-PD Oxford, UK – 6 October, 2020: Oxford Biomedica plc (LSE:OXB)...